[Study on Regulation Effects of Yiqiyangyin Formula on Advanced Lung Cancer Cachexia Mice].

中药材 Pub Date : 2016-06-01

Bin Li, Yan-xiao Li, Hong-ran Pan

{"title":"[Study on Regulation Effects of Yiqiyangyin Formula on Advanced Lung Cancer Cachexia Mice].","authors":"Bin Li, Yan-xiao Li, Hong-ran Pan","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: To observe the effect of Yiqiyangyin formula on advanced lung cancer cachexia mice.Methods: 60 C57 BL /6inbred mice( SPF) were randomly divided into normal control group, model group, Yiqiyangyin formula group,indomethacin group, and cisplatin group, with 12 mice in each group. Model group and normal control group were treated with the same amount of normal saline. Except for the normal control group, the mice of the other groups were built with Lewis lung cancer model. The changes of the level of body mass, feed consumption,serum cytokine,the expression of TNF-α and its receptor were observed.Results: After eight days of treatment, compared with cisplatin group, the levels of CEA,NSE,Pro GRP in serum,CD3+,CD4+,CD4+/ CD8+levels in serum peripheral blood and TNF-R1 expressions in tumor tissues of Yiqiyangyin formula group were increased( P < 0. 05),the contents of TNF-α and IL-6 and the expressions of TNF-α and TNF-R2 in tumor tissues of Yiqiyangyin formula group were significantly decreased( P <0. 05).Conclusion: Yiqiyangyin formula affects on advanced lung cancer cachexia, which may be related to the regulation of the immune and inflammatory cytokines expression.","PeriodicalId":15312,"journal":{"name":"中药材","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中药材","FirstCategoryId":"3","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To observe the effect of Yiqiyangyin formula on advanced lung cancer cachexia mice.

Methods: 60 C57 BL /6inbred mice( SPF) were randomly divided into normal control group, model group, Yiqiyangyin formula group,indomethacin group, and cisplatin group, with 12 mice in each group. Model group and normal control group were treated with the same amount of normal saline. Except for the normal control group, the mice of the other groups were built with Lewis lung cancer model. The changes of the level of body mass, feed consumption,serum cytokine,the expression of TNF-α and its receptor were observed.

Results: After eight days of treatment, compared with cisplatin group, the levels of CEA,NSE,Pro GRP in serum,CD3+,CD4+,CD4+/ CD8+levels in serum peripheral blood and TNF-R1 expressions in tumor tissues of Yiqiyangyin formula group were increased( P < 0. 05),the contents of TNF-α and IL-6 and the expressions of TNF-α and TNF-R2 in tumor tissues of Yiqiyangyin formula group were significantly decreased( P <0. 05).

Conclusion: Yiqiyangyin formula affects on advanced lung cancer cachexia, which may be related to the regulation of the immune and inflammatory cytokines expression.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[益气养阴方对晚期肺癌恶病质小鼠调节作用研究]。

目的:观察益气养阴方对晚期肺癌恶病质小鼠的影响。方法:将60只C57 BL /6自交系小鼠(SPF)随机分为正常对照组、模型组、益气养阴方组、吲哚美辛组、顺铂组，每组12只。模型组与正常对照组均给予等量生理盐水治疗。除正常对照组外，其余各组小鼠均建立Lewis肺癌模型。观察各组体重、采食量、血清细胞因子、TNF-α及其受体表达的变化。结果:治疗8 d后，与顺铂组比较，益气养阴方组患者血清CEA、NSE、Pro GRP水平、外周血CD3+、CD4+、CD4+/ CD8+水平及肿瘤组织中TNF-R1表达均升高(P < 0.05)。结论:益气养阴方对晚期肺癌恶病质的影响可能与调节免疫和炎症细胞因子的表达有关。结论:益气养阴方对晚期肺癌恶病质的影响可能与免疫和炎症细胞因子的表达有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中药材

自引率

0.00%

发文量

11364

期刊介绍： "Chinese Materia Medica" magazine was founded in 1978. It is a national-level academic journal of Chinese medicine science and technology approved by the State Science and Technology Commission and the Press and Publication Administration for public distribution at home and abroad. It is sponsored by the Chinese Materia Medica Information Center of the State Food and Drug Administration and is publicly distributed at home and abroad. It mainly reports on new technologies, new methods and new achievements in the production, scientific research and business management of Chinese medicine, and serves to promote the production and scientific and technological development of Chinese medicine, improve the output and quality of Chinese medicine, improve business management, and prosper the Chinese medicine industry.